Thomas J. Meloro
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, N.Y. 10019-6099, U.S.A.
Thomas J. Meloro is Chair of the Intellectual Property Department and a partner in the Litigation Department of Willkie Farr & Gallagher LLP in New York. Mr. Meloro focuses on litigation and adversarial matters concerning patents, trademarks, and trade secrets. His litigation experience has spanned across technologies and industries ranging from pharmaceuticals to telecommunications, with particular emphasis on pharmaceutical and biologic products, medical products, and consumer products.
Mr. Meloro’s work includes counseling on patent validity, enforceability and infringement, as well as intellectual property issues associated with licensing, mergers and other transactions. Mr. Meloro represents early-stage entities, small and large cap companies, academic institutions, private equity investors and others in such matters.
In his practice at Willkie and previously, Mr. Meloro has represented a variety of major life sciences and technology companies in litigation matters. In the pharmaceutical field, Mr. Meloro has been lead counsel in litigations involving drug products including: paricalcitol (Zemplar), dexmedetomidine (Precedex), diclofenac (Cambia), clindamycin/benzoyl peroxide (Acanya), lansoprazole (Prevacid Solutabs), cefdinir (Omnicef), minocycline (Solodyn), mixed amphetamines (Adderall XR), amlodipine besylate (Norvasc), and amoxiclav (Augmentin).
Mr. Meloro also has significant experience with biologic products, including several trials concerning patents related to recombinant human growth hormone. His clients prevailed after trial and were awarded a judgment that the patent on biosynthetic ripe human growth hormone was invalid and unenforceable for inequitable conduct.
Selected Professional and Business Activities
Mr. Meloro has served as President and a member of the Board of Directors of the New York Intellectual Property Law Association, and is a founding Executive Committee member of the Hon. William C. Conner Inn of Court. He also is a member of the Association of the Bar of the City of New York.
A frequent speaker, Mr. Meloro has lectured on antitrust law for Franklin Pierce Law Center’s Advanced Licensing Institute and contributed a chapter on antitrust issues for Aspen Publishing’s Licensing Update.
Selected Significant Matters
Hospira and Orion v. Sandoz (Precedex) – lead trial counsel in district court judgment protecting the validity and enforceability of the patent for the active ingredient in the sedative Precedex.
Abbott v. Sandoz (Omnicef) – lead trial and appellate counsel in victory for Teva. In an en banc section of the appellate decision, the Federal Circuit sided with Teva concerning standards for establishing infringement of product-by-process patent claims.
GSK v. Geneva (Augmentin) – lead trial and appellate counsel concerning the antibiotic Augmentin. The district court held all seven patents invalid, and the Court of Appeals for the Federal Circuit affirmed the judgment in its entirety in a frequently-cited decision.
Takeda v. Teva (Prevacid Solutabs) – lead appellate counsel in noninfringement victory. The appeal followed a district court judgment that Teva’s product does not infringe the Takeda patent. The Federal Circuit affirmed that judgment just one day after the oral argument, clearing the way for Teva to market its product.
Pfizer v. Synthon (Norvasc) – lead trial and appellate counsel in victory invalidating patent on amlodipine besylate, paving the way for competition on a $2 billion product.
1989, Georgetown University Law Center, J.D.
1986, Manhattan College, B.Ch.E
New York, 1990
- United States Supreme Court
- United States Court of Appeals, Federal Circuit
- United States Court of Appeals, 2nd Circuit